<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.2d1 20170631//EN" "JATS-journalpublishing1.dtd">
      <Volume-Issue>Volume 15, Issue 02, 2023</Volume-Issue>
      <Season>April- June</Season>
      <ArticleType>P'Ceutical Chemistry</ArticleType>
      <ArticleTitle>Cancer’s initiation and progression: Deciphering the role of genetic and epigenetic alterations</ArticleTitle>
          <FirstName>Keshav Taruneshwar</FirstName>
          <FirstName>Pooja A.</FirstName>
      <Abstract>Cancer is a complex disease involving both genetic and epigenetic alterations that drive the transformation of normal cells into malignant ones. In this review, we discuss how genetic mutations and epigenetic changes contribute to cancer initiation and progression. Genetic changes such as mutations, deletions or amplifications of oncogenes and tumor suppressor genes are crucial for the development of most cancers. In addition, epigenetic mechanisms such as DNA methylation, histone modifications and non-coding RNAs are also frequently dysregulated in cancer and contribute to its heterogeneity. A better understanding of the interplay between genetic and epigenetic events will shed light on the molecular mechanisms underlying cancer initiation and progression, and may help identify new therapeutic.</Abstract>
      <Keywords>Cancer, Genetics, Mutations, Progression</Keywords>
        <Abstract>https://isfcppharmaspire.com/ubijournal-v1copy/journals/abstract.php?article_id=14813&amp;title=Cancer’s initiation and progression: Deciphering the role of genetic and epigenetic alterations</Abstract>
        <References>1. CastroMuand;ntilde;oz LJ, Ulloa EV, Sahlgren C, Lizano M, De La Cruz-Hernand;aacute;ndez D, ContrerasParedes A. Modulating epigenetic modifications for cancer therapy (Review). Oncol Rep 2023;49:59.&#13;
2. Hartmaier RJ, Albacker LA, Chmielecki J, Bailey M, He J, Goldberg ME, et al. High-throughput genomic profiling of adult solid tumors reveals novel insights into cancer pathogenesispublic release of adult cancer pathogenesis. Cancer Res 2017;77:2464-75.&#13;
3. Kerick M, Isau M, Timmermann B, Sand;uuml;ltmann H, Herwig R, Krobitsch S, et al. Targeted high throughput sequencing in clinical cancer settings: Formaldehyde fixed-paraffin embedded (FFPE) tumor tissues, input amount and tumor heterogeneity. BMC Med Genomics 2011;4:68.&#13;
4. Feinberg AP, Levchenko A. Epigenetics as a mediator of plasticity in cancer. Science 2023;379:eaaw3835.&#13;
5. Kay J, Thadhani E, Samson L, Engelward B. Inflammation-induced DNA damage, mutations and cancer. DNA Repair (Amst) 2019;83:102673.&#13;
6. Scully R, Panday A, Elango R, Willis NA. DNA doublestrand break repair-pathway choice in somatic mammalian cells. Nat Rev Mol Cell Biol 2019;20:698-714.&#13;
7. Alves-Fernandes DK, Jasiulionis MG. The role of SIRT1 on DNA damage response and epigenetic alterations in cancer. Int J Mol Sci 2019;20:3153.&#13;
8. Louwies T, Ligon CO, Johnson AC, Meerveld BG. Targeting epigenetic mechanisms for chronic visceral pain: A valid approach for the development of novel therapeutics. Neurogastroenterol Motil 2019;31:e13500.&#13;
9. Jand;uuml;hling F, Hamdane N, Crouchet E, Li S, El Saghire H, Mukherji A, et al. Targeting clinical epigenetic reprogramming for chemoprevention of metabolic and viral hepatocellular carcinoma. Gut 2021;70:157-69.&#13;
10. Ilango S, Paital B, Jayachandran P, Padma PR, Nirmaladevi R. Epigenetic alterations in cancer. Front Biosci (Landmark Ed) 2020;25:1058-109.</References>